Novo Nordisk's raised forecast fails to change the debate over its obesity business
CNBC · 49 days ago
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Continue reading at CNBC →Related
Billionaire megadonor spikes his donations to Senate GOP — for not being MAGA enough
The Raw Story · 2 hours ago
Mortgage rates surpass 7% for first time in 2 years amid inflation, Iran war
CBS News · 3 hours ago
Timothy Mellon, a G.O.P. Billionaire, Pulls Back His Money From Senate Republicans
The New York Times · 3 hours ago
Fed's Barr says future interest rate hikes 'likely' needed to tame inflation
The Hill · 5 hours ago
